PhaseBio Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
PhaseBio Pharmaceuticals's earnings have been declining at an average annual rate of -46.4%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 60.2% per year.
Key information
-46.4%
Earnings growth rate
55.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 60.2% |
| Return on equity | n/a |
| Net Margin | -12,572.1% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How PhaseBio Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 1 | -103 | 17 | 0 |
| 31 Mar 22 | 11 | -115 | 17 | 0 |
| 31 Dec 21 | 11 | -131 | 16 | 0 |
| 30 Sep 21 | 11 | -118 | 15 | 0 |
| 30 Jun 21 | 10 | -112 | 14 | 0 |
| 31 Mar 21 | 0 | -111 | 13 | 0 |
| 31 Dec 20 | 0 | -99 | 13 | 0 |
| 30 Sep 20 | 1 | -80 | 13 | 0 |
| 30 Jun 20 | 1 | -66 | 13 | 0 |
| 31 Mar 20 | 2 | -47 | 12 | 0 |
| 31 Dec 19 | 2 | -39 | 11 | 0 |
| 30 Sep 19 | 2 | -33 | 10 | 0 |
| 30 Jun 19 | 2 | -29 | 8 | 0 |
| 31 Mar 19 | 1 | -27 | 6 | 0 |
| 31 Dec 18 | 1 | -24 | 5 | 0 |
| 30 Sep 18 | 0 | -22 | 3 | 0 |
| 30 Jun 18 | 0 | -16 | 3 | -3 |
| 31 Mar 18 | 0 | -12 | 2 | -1 |
| 31 Dec 17 | 0 | -10 | 2 | 0 |
Quality Earnings: 2K4 is currently unprofitable.
Growing Profit Margin: 2K4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2K4 is unprofitable, and losses have increased over the past 5 years at a rate of 46.4% per year.
Accelerating Growth: Unable to compare 2K4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2K4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: 2K4's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.